Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14087092 | 1.00 | EPHX1 (0.50) | EPHX1GRM4OPRM1PSEN1PSEN2 | |
| SCHEMBL14086000 | 1.00 | EPHX1 (0.50) | EPHX1GRM4OPRM1PSEN1PSEN2 | |
| SCHEMBL13538931 | 0.95 | EPHX1 (0.56) | EPHX1GRM4OPRM1CNR2CNR1 | |
| SCHEMBL18464017 | 0.82 | EPHX1 (0.38) | EPHX1GRM4PSEN1PSEN2APH1B | |
| SCHEMBL5909473 | 0.80 | GRM4 (0.56) | EPHX1GRM4CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL12439047 | 0.78 | EPHX1 (0.47) | EPHX1OPRM1MEN1KMT2ACHRNB2 | |
| SCHEMBL14085998 | 0.78 | EPHX1 (0.47) | EPHX1OPRM1MEN1KMT2ACHRNB2 | |
| SCHEMBL22826694 | 0.78 | EPHX1 (0.47) | EPHX1OPRM1MEN1KMT2ACHRNB2 | |
| SCHEMBL30463526 | 0.77 | EPHX1 (0.56) | EPHX1OPRM1CNR2CNR1CA1 | |
| SCHEMBL8198307 | 0.77 | EPHX1 (0.50) | EPHX1GRM4OPRM1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| WO-2023081841-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-21 | — | — | US | disclosed |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3086814-B1 | DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | Bayer Pharma AG (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma AG (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017060322-A2 | PTEFB-INHIBITOR-ADC | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| WO-2016096610-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | KIF23, KIF2C, KIF18A | EPHX1 4503/4885GRM4 3168/4885OPRM1 4338/4885 |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | EPHX1 3354/4885GRM4 3823/4885OPRM1 4739/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | EPHX1 1733/4885GRM4 4567/4885OPRM1 4285/4885 |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | KIF23, KIF5B, KIF2C | EPHX1 4448/4885GRM4 2853/4885OPRM1 4704/4885 |
| US-20180185510-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | EPHX1 3514/4885GRM4 2049/4885OPRM1 4560/4885 |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | TNFSF11, TNFRSF9, CD40 | EPHX1 3880/4885GRM4 3028/4885OPRM1 4849/4885 |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | EPHX1 4448/4885GRM4 2853/4885OPRM1 4704/4885 |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | EPHX1 3643/4885GRM4 2511/4885OPRM1 4577/4885 |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | EPHX1 3354/4885GRM4 3823/4885OPRM1 4739/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | EPHX1 3354/4885GRM4 3823/4885OPRM1 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.